Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04170920 · ClinicalTrials.gov registry record · NA

Pilot Study of a an App to Improve Medication Adherence in Breast Cancer Survivors Receiving AIs

A NA study, sponsored by Indiana University.

Completed
Registry status
NA
Development phase
62
Enrollment target

NCT04170920 is a NA study that has completed, run by Indiana University. The registered enrollment target is 62 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04170920, a NA study, has completed, sponsored by Indiana University.

COMPLETED
Registry status
NA
Development phase
62 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate the feasibility of an mobile-health strategy to improve patient-reported symptoms, promote life-saving medication adherence, and encourage healthy lifestyle behaviors in early stage breast cancer survivors receiving adjuvant Aromatase inhibitors, while beginning to predict psycho-social and demographic characteristics of those who benefit most from this approach. This will provide preliminary experience and evidence for larger, randomized clinical trials evaluating this methodology, which will have immediate and scalable influence on cancer survivor ship.

Interventions

  • DEVICE LifeExtend-AI

Trial Details

FieldValue
Enrollment Target 62 participants
Start Date 2020-02-17
Est. Completion 2022-08-09
Phase NA

Sponsor

Indiana University

890 total trials

What the Registry Record Tells You About NCT04170920

The ClinicalTrials.gov registry entry for NCT04170920 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which LifeExtend-AI is the first listed.

NCT04170920 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04170920 about?

NCT04170920 is a clinical study titled "Pilot Study of a an App to Improve Medication Adherence in Breast Cancer Survivors Receiving AIs". The purpose of this study is to evaluate the feasibility of an mobile-health strategy to improve patient-reported symptoms, promote life-saving medication adherence, and encourage healthy lifestyle behaviors in early stage breast cancer survivors receiving adjuvant Aromatase inhibitors, while beginn...

What is the current status of trial NCT04170920?

This trial is currently completed. It is a NA study. The enrollment target is 62 participants. The study started on 2020-02-17. Estimated completion is 2022-08-09.

What interventions are being tested in trial NCT04170920?

The interventions under investigation include: LifeExtend-AI (DEVICE).

Who is sponsoring clinical trial NCT04170920?

This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.